Achieving greater reductions in cardiovascular risk: Lessons from statin therapy on risk measures and risk reduction

American Heart Journal

Volumn 148, Issue 1 SUPPL., 2004, Pages

  Ballantyne, Christie M ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTILIPEMIC AGENT; ANTIOXIDANT; APOLIPOPROTEIN B; ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; SIMVASTATIN; BIOLOGICAL MARKER; LIPOPROTEIN;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONFERENCE PAPER; CORRELATION ANALYSIS; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; DISEASE MARKER; DRUG EFFECT; DRUG EFFICACY; DRUG TARGETING; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; SECONDARY PREVENTION; TREATMENT INDICATION; ARTICLE; BLOOD; CORONARY ARTERY DISEASE; HYPERLIPIDEMIA; REFERENCE VALUE;

ANTILIPEMIC AGENTS; APOLIPOPROTEINS B; BIOLOGICAL MARKERS; CHOLESTEROL, LDL; CLINICAL TRIALS; CORONARY DISEASE; HUMANS; HYPERLIPIDEMIAS; LIPOPROTEINS; REFERENCE VALUES;

EID: 3042848580     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ahj.2004.04.025     Document Type: Conference Paper

References (19)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 285:2001;2486-2497
2. Fedder D.O., Koro C.E., L'Italien G.J. New National Cholesterol Education Program III guidelines for primary prevention lipid-lowering drug therapy projected impact on the size, sex, and age distribution of the treatment-eligible population. Circulation. 105:2002;152-156
3. Jacobson T.A., Schein J.R., Williamson A., et al. Maximizing the cost-effectiveness of lipid-lowering therapy. Arch Intern Med. 158:1998;1977-1989
4. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals a randomised placebo-controlled trial. Lancet. 360:2002;7-22
5. Sever P.S., Dahlöf B., Poulter N.R., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-then-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA) a multicentre randomised controlled trial. Lancet. 361:2003;1149-1158
6. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 288:2002;2998-3007
7. Gotto A.M. Jr, Whitney E., Stein E.A., et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation. 101:2000;477-484
8. Sniderman A.D., Furberg C.D., Keech A., et al. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet. 361:2003;777-780
9. Schneck D.W., Knopp R.H., Ballantyne C.M., et al. Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease. Am J Cardiol. 91:2003;33-41
10. Ballantyne C.M., Andrews T.C., Hsia J.A., et al. Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels. Am J Cardiol. 88:2001;265-269
11. Jacobson T.A., Griffiths G.G., Varas C., et al. Impact of evidence-based "clinical judgment" on the number of American adults requiring lipid-lowering therapy based on updated NHANES III data. National Health and Nutrition Examination Survey. Arch Intern Med. 160:2000;1361-1369
12. Pearson T.A., Laurora I., Chu H., et al. The Lipid Treatment Assessment Project (L-TAP). A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 160:2000;459-467
13. Andrews T.C., Ballantyne C.M., Hsia J.A., et al. Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins. Am J Med. 111:2001;185-191
14. Grundy S.M. Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy. Circulation. 106:2002;2526-2529
15. Walldius G., Jungner I., Holme I., et al. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study) a prospective study. Lancet. 358:2001;2026-2033
16. Collins R., Armitage J., Parish S., et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes a randomised placebo-controlled trial. Heart Protection Study Collaborative Group. Lancet. 361:2003;2005-2016
17. Ridker P.M., Rifai N., Clearfield M., et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 344:2001;1959-1965
18. Ridker P.M., Rifai N., Rose L., et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 347:2002;1557-1565
19. Ridker P.M. JUPITER Study Group. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein rationale and design of the JUPITER trial. Circulation. 108:2003;2292-2297